Research Topics
| Scott M HammerSummaryAffiliation: Columbia University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Combining Google Earth and GIS mapping technologies in a dengue surveillance system for developing countriesAileen Y Chang
Department of Vector Borne Disease, Nicaraguan Ministry of Health, Managua, Nicaragua
Int J Health Geogr 8:49. 2009..A surveillance system using Google Earth and GIS mapping technologies was developed in Nicaragua as a management tool...- A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimenScott M Hammer
Division of Infectious Diseases, Columbia University, New York, New York 10032, USA
HIV Clin Trials 11:312-24. 2010..The objective of AIDS Clinical Trials Group Study 372A was to determine whether the intensification strategy of adding abacavir to an effective indinavir-dual nucleoside regimen would delay the time to virologic failure... 
Clinical practice. Management of newly diagnosed HIV infectionScott M Hammer
Division of Infectious Diseases, Columbia University Medical Center, New York 10032, USA
N Engl J Med 353:1702-10. 2005
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panelScott M Hammer
Division of Infectious Diseases, Columbia University College of Physicians and Surgeons, 630 W 168th St, New York, NY 10032, USA
JAMA 300:555-70. 2008....- Antiretroviral guidelines for resource-limited settings: the WHO's public health approachScott M Hammer
Columbia University College of Physicians and Surgeons, New York, NY, USA
Nat Med 8:649-50. 2002 - Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trialScott M Hammer
Division of Infectious Diseases, Department of Medicien, Columbia University College of Physicians and Surgeons, 630 W 168th St, New York, NY 10032, USA
JAMA 288:169-80. 2002..Management of antiretroviral treatment failure in patients receiving protease inhibitor (PI)-containing regimens is a therapeutic challenge... - A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavirScott M Hammer
Columbia University, New York, NY, USA
Antivir Ther 8:507-18. 2003 - Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panelScott M Hammer
Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
JAMA 296:827-43. 2006..The International AIDS Society-USA panel has updated its recommendations as warranted by new developments in the field... - A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus diseaseMargaret A Fischl
Department of Medicine, University of Miami School of Medicine, Miami, Florida 33101, USA
J Infect Dis 188:625-34. 2003..A 4-drug regimen containing efavirenz plus indinavir resulted in a superior virologic response, whereas one containing nelfinavir plus indinavir resulted in an inferior response and a greater likelihood of toxicity... - Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjectsRobert Dicenzo
University at Buffalo, Buffalo, New York, USA
Antimicrob Agents Chemother 47:1929-35. 2003..Abacavir did not influence the pharmacokinetics or exposure parameters of either indinavir or efavirenz. The levels of efavirenz exposure were similar in subjects receiving efavirenz q12h or q24h... - Highlights of the 15th Conference on Retroviruses and Opportunistic Infections. Advances in antiretroviral therapyTimothy J Wilkin
Weill Medical College of Cornell University, New York, NY, USA
Top HIV Med 16:31-60. 2008.... - Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patientsElias K Halvas
Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA
J Infect Dis 201:672-80. 2010.... - Advances in antiretroviral therapyMagdalena E Sobieszczyk
Columbia University Medical Center, New York, NY, USA
Top HIV Med 14:36-62. 2006.... - The challenge of HIV-1 subtype diversityBarbara S Taylor
Department of Medicine and the Division of Infectious Diseases, Columbia University Medical Center, New York 10032, USA
N Engl J Med 358:1590-602. 2008 - Advances in antiretroviral therapyJoyce Jones
Columbia University Medical Center, New York, NY, USA
Top HIV Med 15:48-82. 2007..Research in antiretroviral therapy remains dynamic and advances in the field continue to improve our ability to maintain long-term control of HIV-1 replication in infected persons... - Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final resultsPaul E Sax
Division of Infectious Diseases, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
J Infect Dis 204:1191-201. 2011..Due to higher virologic failure with ABC/3TC in the high HIV RNA stratum, blinded treatment was stopped in this group, but study follow-up continued for all patients... - Advances in antiretroviral therapyTimothy J Wilkin
Weill Medical College of Cornell University, New York, NY, USA
Top HIV Med 17:68-88. 2009.... - Advances in antiretroviral therapyMagdalena E Sobieszczyk
Columbia University College of Physicians and Surgeons, New York, NY, USA
Top HIV Med 13:24-44. 2005..This review will highlight the major findings relevant to clinicians and clinical investigators... - The relationship between genotypic sensitivity score and treatment outcomes in late stage HIV disease after supervised HAARTDelivette Castor
Columbia University, New York, New York 10032, USA
J Med Virol 81:1323-35. 2009..233, P = 0.92), occurrence of new AIDS defining category C conditions or death. These data support resistance testing-guided therapy as an independent predictive factor to improve virologic responses in treatment-experienced patients... - Increasing choices for HIV therapyScott M Hammer
Columbia Presbyterian Medical Center, New York, NY 10032, USA
N Engl J Med 346:2022-3. 2002 - Advances in antiretroviral therapyBarbara Taylor
Division of Infectious Diseases, University of Texas, San Antonio, TX, USA
Top Antivir Med 19:69-97. 2011..Prevention of mother-to-child transmission continued to be an important part of the conference... - Advances in antiretroviral therapySusan Olender
Columbia University Medical Center, New York, NY, USA
Top Antivir Med 20:61-86. 2012..In resource-limited settings (RLS), prevention of mother-to-child transmission (PMTCT) and ART scale-up remained priorities. New data on antiretroviral resistance in RLS and on the implications of low-frequency mutations were presented... - Immunologic markers as predictors of tuberculosis-associated immune reconstitution inflammatory syndrome in HIV and tuberculosis coinfected persons in ThailandHong Van Tieu
Department of Medicine, Division of Infectious Diseases, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
AIDS Res Hum Retroviruses 25:1083-9. 2009..IFN-gamma, IL-2, and IL-12 responses did not differ between TB-IRIS and no TB-IRIS subjects (p > 0.05). More research into the immunopathogenesis of TB-IRIS and diagnostic potential of cytokine markers is warranted... - Advances in antiretroviral therapyTimothy J Wilkin
Weill Cornell Medical College, New York, NY, USA
Top HIV Med 18:66-92. 2010..Several interesting smaller studies were focused on HIV-1 pathogenesis and persistent viremia... - Cornell/amfAR Symposium. Strategies of antiretroviral therapyScott M Hammer
Columbia Presbyterian Medical Center, New York, USA
AIDS Read 12:257-60, 262. 2002..Once the decision is made to start therapy, a regimen and treatment strategy that have the best chance to achieve maximal and durable suppression of viral replication for the particular patient must be chosen... - Advances in antiretroviral therapyMary A Albrecht
Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
Top HIV Med 11:97-127. 2003 - Advances in antiretroviral therapy. Highlights of the 11th Conference on Retroviruses and Opportunistic Infections, February 8-11, 2004, San Francisco, California, USAMagdalena E Sobieszczyk
Columbia University College of Physicians and Surgeons, New York, NY, USA
Top HIV Med 12:9-29. 2004..This reviews summarizes new information relevant to clinicians and clinical researchers... - Acceptability of male circumcision for the prevention of HIV among high-risk heterosexual men in ThailandHong Van Tieu
Division of Infectious Diseases, Department of Medicine, Columbia University College of Physicians and Surgeons, 630 West 168th Street, New York, NY 10032, USA
Sex Transm Dis 37:352-5. 2010..14.2% and 24.9% expressed willingness to be circumcised before and after circumcision education, respectively. Neonatal circumcision acceptability was relatively high. One participant underwent circumcision at 3-month follow-up... - Transmitted drug resistance among antiretroviral-naive patients with established HIV type 1 infection in Santo Domingo, Dominican Republic and review of the Latin American and Caribbean literatureJulie E Myers
Division of Infectious Diseases, Columbia University Medical Center, New York, NY 10032, USA
AIDS Res Hum Retroviruses 28:667-74. 2012..Ongoing surveillance is clearly needed to better understand the TDR phenomenon in the Caribbean... - Low bone mass and high bone turnover in postmenopausal human immunodeficiency virus-infected womenMichael T Yin
M S, Division of Infectious Diseases, Columbia University Medical Center, 630 West 168th Street, PH8 876, New York, New York 10032, USA
J Clin Endocrinol Metab 95:620-9. 2010..Conclusion: The lower BMD, higher prevalence of low BMD, and higher levels of bone turnover markers detected in HIV+ postmenopausal minority women could place them at high risk for future fractures... - Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infectionsMagdalena E Sobieszczyk
Department of Medicine, Division of Infectious Diseases, Columbia University College of Physicians and Surgeons, 630 W 168th Street, PH 8W 876, New York, NY 10032, USA
J Antimicrob Chemother 54:566-9. 2004..The treatment of infections caused by multidrug-resistant (MDR) Gram-negative organisms poses a therapeutic challenge. The use of polymyxin B has been resurrected specifically for this purpose... - Nucleoside analogue reverse transcriptase inhibitor options: a re-examination of the classScott M Hammer
Columbia University Medical Center, New York, NY, USA
Top HIV Med 14:140-3. 2006..The article summarizes a presentation on nRTIs made by Scott M. Hammer, MD, at the International AIDS Society-USA course in New York in March 2006. The original presentation is available as a Webcast at www.iasusa.org... - Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavirMarc Pfister
Departments of Laboratory Medicine and Biopharmaceutical Sciences, University of California-San Francisco, San Francisco, CA 94143-0626, USA
Clin Pharmacol Ther 72:133-41. 2002..Amprenavir intrinsic clearance apparently increases by more than 30% between weeks 2 and 24, possibly because of the time course of CYP3A4 induction... - Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA PanelPatrick G Yeni
Hopital Bichat Claude Bernard, Department of Infectious Diseases, 46 rue Henri Huchard, Paris, Cedex 18 France 75877
JAMA 288:222-35. 2002..These updated recommendations are intended to guide practicing physicians actively involved in human immunodeficiency virus (HIV)- and acquired immunodeficiency syndrome (AIDS)-related care... - Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398Marc Pfister
Department of Laboratory Medicine and Biopharmaceutical Sciences, University of California, San Francisco, San Francisco, California 94143, USA
Antimicrob Agents Chemother 47:130-7. 2003..0003). Among NNRTI-experienced patients, however, hazard is relatively uncorrelated with EFV CL/F... - Detection of replication-competent human immunodeficiency virus type 1 (HIV-1) in cultures from patients with levels of HIV-1 RNA in plasma suppressed to less than 500 or 50 copies per milliliterLisa M Demeter
University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
J Clin Microbiol 40:2089-94. 2002..The delay in the time required for HIV cultures to turn positive should be considered when attempting to obtain an HIV isolate from patients with suppression of plasma viral load... - Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapyCamlin Tierney
Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts 02115, USA
J Infect Dis 187:144-8. 2003..03). Only DNA level was significantly associated with survival (adjusted hazard ratio for 1 log(10) higher level, 3.99; 95% confidence interval, 1.44-11.09; P=.008)... - Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA PanelMartin S Hirsch
Harvard Medical School, Boston, MA, USA
Clin Infect Dis 37:113-28. 2003..Limitations of resistance testing remain, and more study is needed to refine optimal use and interpretation... - HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patientsJudith Falloon
Laboratory of Immunoregulation, NIAID, National Institutes of Health, Building 10 Room 11C103, 10 Center Drive, Bethesda, MD 20892-1880, USA
AIDS 16:387-96. 2002..Baseline viral load and some genotypic and phenotypic markers of resistance correlated with HIV RNA response... - What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trialsPeter B Gilbert
Statistical Center for HIV Aids Research and Prevention, Fred Hutchinson Cancer Research Center, University of Washington, 1100 Fairview Avenue North, Seattle, WA 98109, USA
J Infect Dis 188:179-93. 2003..The assessment suggests that a vaccine demonstrating moderately durable effects to delay therapy and to ameliorate viremia merits consideration for licensure... - Single-dose nevirapine and drug resistance: the more you look, the more you findScott M Hammer
J Infect Dis 192:1-3. 2005 - Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individualsEdward P Acosta
Division of Clinical Pharmacology, University of Alabama at Birmingham School of Medicine, Birmingham, AL 35294 0019, USA
J Acquir Immune Defic Syndr 37:1358-66. 2004.... - HIV-1 drug resistance in subjects with advanced HIV-1 infection in whom antiretroviral combination therapy is failing: a substudy of AIDS Clinical Trials Group Protocol 388Lisa M Demeter
Infectious Diseases Unit, University of Rochester, Rochester, New York 14642, USA
Clin Infect Dis 39:552-8. 2004..Thus, although dual resistance to efavirenz and lamivudine occurred at VF in the efavirenz-indinavir arm, this risk was relatively low when evaluated in the context of the potency and tolerability of this regimen... - Impact of indinavir on the quality of life in patients with advanced HIV infection treated with zidovudine and lamivudinePaul M Coplan
Merck Research Laboratories, West Point, PA 19486, USA
Clin Infect Dis 39:426-33. 2004..Patients receiving triple-drug therapy also had significantly better role function, energy, and pain scores than did patients treated with dual-drug therapy... - Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA PanelPatrick G Yeni
Department of Infectious Diseases, Hopital Bichat Claude Bernard, X Bichat Medical School, Paris, France
JAMA 292:251-65. 2004..Substantial changes in the field of human immunodeficiency virus (HIV) treatment have occurred in the last 2 years, prompting revision of the guidelines for antiretroviral management of adults with established HIV infection... - Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118)Barbara M Gripshover
University Hospitals of Cleveland, Case Western Reserve University, Cleveland, OH, USA
Antivir Ther 11:619-23. 2006..Amdoxovir (2,6-diaminopurine dioxolane; DAPD) is a nucleoside reverse transcriptase inhibitor (NRTI) of human immunodeficiency virus-1 (HIV-1) with activity against wild-type and NRTI-resistant viruses... - Detection of drug-resistant minority variants of HIV-1 during virologic failure of indinavir, lamivudine, and zidovudineCarrie Dykes
University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
J Infect Dis 189:1091-6. 2004..Selection for indinavir-resistant variants on treatment with indinavir, lamivudine, and zidovudine may occur slowly, depending on the genetic context in which they arise... - Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panelMartin S Hirsch
Harvard Medical School, Boston, Massachusetts, USA
Clin Infect Dis 47:266-85. 2008..As the roll out of antiretroviral therapy continues in developing countries, drug resistance monitoring for both subtype B and non-subtype B strains of HIV will become increasingly important... - Questions to and answers from the International AIDS Society-USA Resistance Testing Guidelines PanelMartin S Hirsch
Top HIV Med 11:150-4. 2003..We are happy to feature the latest edition in this issue of Topics in HIV Medicine. It is our hope that addressing these issues will help guide your treatment strategy decisions regarding resistance testing... - Patents versus patients? Antiretroviral therapy in IndiaDiane V Havlir
University of California, San Francisco, USA
N Engl J Med 353:749-51. 2005 - HIV vaccine research: the way forwardAnthony S Fauci
National Institute of Allergy and Infectious Diseases, National Institutes of Health, 31 Center Drive, Bethesda, MD 20892, USA
Science 321:530-2. 2008..This article summarizes progress and challenges in HIV vaccine research, the priorities arising from a recent summit at NIAID, and the actions needed, some already under way, to address those priorities... - The challenge of HIV-1 subtype diversityBarbara S Taylor
N Engl J Med 359:1965-6. 2008
Research Grants
- Columbia Collaborative HIV/AIDS Clinical Trials UnitScott Hammer; Fiscal Year: 2007..Integrating HIV prevention and therapeutic research at the CTU level is an effective model for the rapid translation of study results into improvements in care and public health. ADMINISTRATIVE COMPONENT: ..
- COLUMBIA-ADARC-CORNELL AIDS CLINICAL TRIALS UNITScott Hammer; Fiscal Year: 2006..Thus, the Columbia-ADARC ACTU will be an active participant in the Group's mission to improve the health of HIV infected individuals and set standards for treatment of HIV disease. ..